Earnings Snapshot: Teva Pharmaceutical Industries tops Q1 estimates; maintains 2026 business outlook
Source: SeekingAlpha
2026-04-29 08:39:56 ET
More on Teva Pharmaceutical
- Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy
- Teva: Shedding The Generics Skin To Reveal A Fairly Priced, Branded Powerhouse
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Teva cuts 2026 outlook despite Q1 beat to reflect Emalex buyout
- Teva Pharmaceutical beats top-line and bottom-line estimates; reaffirms FY26 outlook
Read the full article on Seeking Alpha
For further details see:
Earnings Snapshot: Teva Pharmaceutical Industries tops Q1 estimates; maintains 2026 business outlook
Teva- Pharmaceutical Industries Ltd.
NASDAQ: TEVJF
TEVJF Trading
0.0% G/L:
$30.19 Last:
250 Volume:
$30.19 Open:
TEVJF Latest News
June 06, 2025 09:44:00 am
Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building
$39,634,050,594
1,138,314,769
N/A
264
N/A
Pharmaceuticals
Healthcare
IL
Tel Aviv
